Back to Trial

Oracle Runs

Oracle findings and outcome history for Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa (NCT06555328).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 6:38 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Sponsor publicly reported positive topline Phase 2a data for INF904 in HS and CSU and described the trial as successful, with encouraging clinical activity and no safety signals of concern. ClinicalTrials.gov matches NCT06555328 as the exact Phase 2a basket study in these indications.

Sources
Sponsorinflarx.de11/10/25
11-2025-InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU)

InflaRx announced positive topline Phase 2a data; the release says INF904 showed strong efficacy potential with no safety signals of concern, and management called the Phase 2a trial a success.

View source
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06555328 | Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

ClinicalTrials.gov identifies NCT06555328 as the exact Phase 2a open-label basket study of INF904 in moderate to severe CSU or hidradenitis suppurativa.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted98% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Sponsor publicly reported positive topline Phase 2a data for INF904 in HS and CSU and described the trial as successful, with encouraging clinical activity and no safety signals of concern. ClinicalTrials.gov matches NCT06555328 as the exact Phase 2a basket study in these indications.

Found Apr 1, 2026, 6:38 PMOutcome date Nov 10, 2025, 12:00 AMReviewed Apr 1, 2026, 6:46 PM
Sponsorinflarx.deNov 10, 2025, 12:00 AM
11-2025-InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU)
InflaRx announced positive topline Phase 2a data; the release says INF904 showed strong efficacy potential with no safety signals of concern, and management called the Phase 2a trial a success.
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06555328 | Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
ClinicalTrials.gov identifies NCT06555328 as the exact Phase 2a open-label basket study of INF904 in moderate to severe CSU or hidradenitis suppurativa.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 6:46 PM

Will the results be positive?

PendingtoYEScurrentYES
GPT-5.4 (OpenAI)98% confidenceReviewed Apr 1, 2026, 6:46 PM

Sponsor publicly reported positive topline Phase 2a data for INF904 in HS and CSU and described the trial as successful, with encouraging clinical activity and no safety signals of concern. ClinicalTrials.gov matches NCT06555328 as the exact Phase 2a basket study in these indications.